Sunday, October 6, 2024
10/6/2024
ABSTRACT: Fibrotic disorders represent a major health problem in the U.S, with a rising incidence (particularly among the elderly). Idiopathic pulmonary fibrosis (IPF) is a relentless and fatal fibrotic disease, characterized by progressive scar tissue formation in the lungs, resulting respiratory failure. There are two FDA-approved treatments for IPF, which slow but do not stop the decline in lung function, and only have a modest survival benefit. Improved therapies for IPF and other fibrotic diseases are needed to improve patient quality of life and outcomes. We were the first to identify Nox4 (an oxidant generating enzyme) as a critical mediator of lung fibrosis. Nox4 is now considered to be a core pathway that mediates fibrosis in various organs (lungs, liver, skin, kidney, blood vessels, skeletal muscle, and heart). We have also demonstrated that Nox4 becomes dysfunctional in aging, where its sustained upregulation promotes age-associated persistent/progressive fibrosis – These findings may help to explain why fibrotic disorders develop are more prevalent among the elderly. Although Nox4 is among the most promising drug targets for fibrotic disease, selective Nox4 inhibitors have yet to be successfully developed – until now. This direct to Phase II SBIR application is a collaboration between biotech startup company Fibronox LLC and Emory University. We have pioneered the development of first-in-class selective Nox4 inhibitor drug candidates; 10 patents filed. Our Nox4 inhibitors have passed a rigorous screening cascade, including nM potency in vitro for inhibiting TGFb-induced pro-fibrotic effects and reversing IPF myofibroblast phenotypes. Importantly, therapeutic treatment with Nox4 inhibitor candidates in vivo led to protection from the development of fibrosis and promoted the resolution of age-associated established fibrosis. Further, inhaled delivery of Nox4 inhibitors demonstrated efficacy at a dose ~7-fold lower than orally administered and 4-fold increased drug exposure in the lung. The goal of the proposed studies is to perform side-by-side evaluation of our top 3 most promising candidates via inhaled delivery in order to identify one development candidate for IND-enabling studies and subsequent clinical development. Aim 1 will rigorously validate top candidates for selectivity and mode of action. Aim 2 will de-risk top candidates through advanced screening, including the use of human precision cut lung slices, single-cell RNAseq, and highly a innovative bioinformatic approach to evaluate Nox4 inhibitors vs. standard of care. Aim 3 will evaluate specificity and potential for adverse effects. Aim 4 will determine the therapeutic index and maximum tolerated dose. To date, no therapeutics have been shown to reverse age- associated established fibrosis, which may represent the holy grail for therapeutic strategies to more effectively treat IPF. We hypothesize that therapeutic strategies targeting age-associated pathologic mechanisms (ex. age- dependent sustained Nox4/ROS levels) offer the greatest potential for developing successful IPF treatments.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
